SOTERIA and Tempus Join Forces on Precision Cancer Care for Military Communities
SOTERIA Precision Medicine Foundation is collaborating with Tempus to provide personalized cancer treatment insights and advanced genomic sequencing to U.S. active-duty service members and veterans. The work supports SOTERIA’s Cancer Hunt initiative, which combines patient navigation with Tempus’ genomic profiling and AI-enabled diagnostic platform.
- SOTERIA and Tempus are collaborating on precision oncology for U.S. active-duty service members and veterans.
- Tempus will provide comprehensive genomic profiling and an AI-enabled diagnostic platform.
- SOTERIA’s Cancer Hunt initiative includes patient navigation and CLIA-validated germline and somatic sequencing.
- The organizations will continue molecular profiling and data integration across SOTERIA’s patient cohort.
Genomic profiling for military patients
SOTERIA, a non-profit 501(c)(3) organization, said the collaboration will help identify targeted therapies and clinical trial opportunities for members of military communities diagnosed with cancer. Tempus will contribute comprehensive genomic profiling and its AI-enabled diagnostic platform.
The initiative is designed to support precision oncology, an approach that uses information about a patient’s cancer and molecular profile to inform treatment decisions. SOTERIA said its Cancer Hunt program provides precision oncology patient navigation and facilitates CLIA-validated germline and somatic sequencing.
Addressing a reported care gap
According to SOTERIA, members of military communities are increasingly being diagnosed with cancer at younger ages and at advanced stages. The foundation said it aims to address this care gap by helping patients access molecular data that can inform their care when possible.
“Our mission is to ensure that patients have access to the tools and technology that can inform the most effective treatment path for them,” Julia Civardi, SOTERIA’s founder and CEO, said in the announcement. She added that Tempus’ genomic sequencing and AI analytics could turn complex molecular data into “clear, actionable treatment options” for patients and care teams.
Research and care pathway integration
Through the collaboration, Tempus and SOTERIA will continue to streamline molecular profiling and data integration across SOTERIA’s patient cohort. The organizations said this work will advance precision oncology research and optimize care pathways for military community members diagnosed with cancer.
Ezra Cohen, M.D., chief medical officer of oncology at Tempus, said the collaboration will put genomic insights in the hands of clinicians and patients “when every decision matters most.” CAPT Rob Newson, SEAL, USN (RET), PhD, SOTERIA’s chief community officer, said the initiative reflects what is possible when technological innovation and service come together to support military families.
SOTERIA provides information about the Cancer Hunt initiative and consultation calls with its nurse navigators through its website. The announcement does not specify the number of patients involved or provide details about treatment outcomes.
